Literature DB >> 6141177

Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man.

W K Ward, J D Best, J B Halter, D Porte.   

Abstract

To determine the effect of isolated beta-cell impairment on glucose turnover, we administered a 46-h infusion of somatostatin (200 micrograms/h) with glucagon replacement (0.75 ng/kg X min) to eight normal men. Fasting plasma insulin levels fell slightly, but significantly, from 8 +/- 2 (+/- SEM; control) to 6 +/- 2 microU/ml 46 h after beginning the infusion (P less than 0.001). Over the same period, fasting plasma glucose rose from 89 +/- 2 to 114 +/- 2 mg/dl (P less than 0.001), and plasma glucagon levels remained unchanged (79 +/- 5 vs. 82 +/- 8 pg/ml P = NS). Glucose turnover was measured by isotope dilution using [3-3H]glucose. The glucose production rate rose consistently from a baseline value of 2.08 +/- 0.04 to 2.45 +/- 0.06 mg/kg X min (P less than 0.01). The glucose disposal rate also rose consistently from 2.11 +/- 0.04 to 2.53 +/- 0.09 mg/kg X min (P less than 0.01). We conclude that prolonged mild selective insulin deficiency produced by infusion of somatostatin with glucagon replacement in normal men causes an elevation of the fasting plasma glucose level, which is maintained by glucose overproduction rather than by glucose underutilization. Overproduction of glucose may also be important in maintaining basal hyperglycemia in patients with noninsulin-dependent diabetes mellitus who have a similar impairment of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141177     DOI: 10.1210/jcem-58-3-449

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.

Authors:  Puneet Gaitonde; Parag Garhyan; Catharina Link; Jenny Y Chien; Mirjam N Trame; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

2.  Hyperglucagonemia and insulin-mediated glucose metabolism.

Authors:  S Del Prato; P Castellino; D C Simonson; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

3.  Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients.

Authors:  F Jahoor; D N Herndon; R R Wolfe
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

4.  Glucagon supports postabsorptive plasma glucose concentrations in humans with biologically optimal insulin levels.

Authors:  Benjamin A Cooperberg; Philip E Cryer
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

5.  Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study.

Authors:  Steven E Kahn; Kieren J Mather; Silva A Arslanian; Elena Barengolts; Thomas A Buchanan; Sonia Caprio; David A Ehrmann; Tamara S Hannon; Santica Marcovina; Kristen J Nadeau; Kristina M Utzschneider; Anny H Xiang; Sharon L Edelstein
Journal:  Diabetes Care       Date:  2021-06-15       Impact factor: 17.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.